Question explored with the scientific record
Is a statin like Crestor worth the risk
The short version: Crestor (rosuvastatin) lowers LDL and reduces cardiovascular events in some groups, but the absolute benefit is small, the evidence is thinner than advertised, and the risks—especially diabetes and muscle problems—are real and dose-dependent.
The JUPITER trial, which is the main evidence for rosuvastatin in people without existing heart disease, found that 20 mg daily cut the combined risk of heart attack, stroke, and death by about 44% [1]. That sounds big, but the absolute numbers tell a different story: in the placebo group, about 1.2 in 100 had a major event each year; in the rosuvastatin group, about 0.8 in 100 did [1]. That is a difference of roughly 4 people per 1,000 per year. A broader meta-analysis of 21 statin trials found an even smaller absolute reduction in all-cause mortality of just 0.8% [2]. For primary prevention in women, the mortality benefit was not statistically significant at all [1].
The same JUPITER trial also found that rosuvastatin increased the rate of physician-reported diabetes in women by about 50% (1.53 vs 1.03 per 100 person-years) [1]. A 2021 meta-analysis of 62 primary prevention trials found that rosuvastatin was the only statin with a statistically significant increase in muscle symptom complaints [5]. A case report showed that a woman who developed liver injury on simvastatin had it recur when switched to rosuvastatin, suggesting a class effect [3]. The drug also crosses the blood-brain barrier in animal models, which may affect brain cholesterol synthesis [6].
The evidence for benefit is strongest in people who already have had a heart attack or stroke. For primary prevention in healthy people, the benefit is small enough that you have to treat about 100 people for a year to prevent one event [7]. Meanwhile, about 5 to 20 in 100 people on statins report muscle symptoms, though some of that is the nocebo effect [4, 5].
| Group | Outcome | Rosuvastatin | Placebo | Difference per 1,000/year |
|---|---|---|---|---|
| JUPITER (primary prevention) | Major CVD event | ~8 | ~12 | ~4 fewer |
| JUPITER women | Incident diabetes | 15.3 | 10.3 | ~5 more |
| Meta-analysis (21 RCTs) | All-cause mortality | - | - | ~8 fewer per 1,000 over trial |
My call: for someone with established heart disease, the benefit likely outweighs the risk. For a healthy person taking it to prevent future disease, the benefit is too small to justify the diabetes and muscle risks. Confidence: moderate.
Sources used 7
-
Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia
In JUPITER, rosuvastatin reduced primary CVD events similarly in women and men with elevated hsCRP and low LDL; a meta-analysis of women in primary prevention trials found statins reduced CVD by about one-third, with a nonsignificant mortality reduction.
DOI: 10.1161/circulationaha.109.906479 -
Statin Use and the Risk of All-cause Mortality
Statins reduced all-cause mortality in some trials, but a meta-analysis found only a 0.8% absolute reduction, leaving the effect uncertain and prompting calls for trials with all-cause mortality as the primary endpoint.
DOI: 10.3904/kjm.2023.98.1.4 -
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect?
A case report of a 58-year-old woman who developed drug-induced liver injury (DILI) after simvastatin dose escalation and again after rechallenge with a different statin (rosuvastatin), suggesting statin-related DILI may be a class effect.
DOI: 10.1515/jbcpp-2021-0013 -
impact of the nocebo effect on discontinuation of statin therapy due to myopathy in patients with cardiovascular disease – a review
This narrative review synthesizes randomized and observational evidence that the nocebo effect substantially drives patient-reported muscle symptoms during statin therapy and that true statin-induced myopathy is rarer than patient reports suggest.
DOI: 10.12775/qs.2024.31.55769 -
Statin-Induced Myopathy
This narrative review concludes that statin-associated muscle symptoms are common in practice and multifactorial, but randomized evidence shows no significant difference from placebo and no confirmed muscle disease, supporting a substantial nocebo component.
DOI: 10.30895/2312-7821-2023-11-3-252-270 -
Brain Cholesterol Synthesis in Mice Is Affected by High Dose of Simvastatin but Not of Pravastatin
High-dose, short-term simvastatin crosses the blood-brain barrier in mice and reduces brain cholesterol synthesis (lower lathosterol and higher HMG-CoA reductase mRNA), while pravastatin does not, with brain cholesterol turnover remaining unchanged.
DOI: 10.1124/jpet.105.094136 -
Statins for Primary Prevention
The paper critiques the US Preventive Services Task Force's recommendations on statin use for primary prevention of cardiovascular disease, highlighting the weak evidence supporting these guidelines and the potential harms of statin therapy in asymptomatic patients.
DOI: 10.1001/jamainternmed.2016.7585